What it sells
Early detection of Alzheimer's disease
Business model breakdown
Buyer: who owns the budget?
Physicians and healthcare providers evaluating mild cognitive impairment patients; also pharma.
Trigger: what makes them buy now?
Need prognosis of progression from aMCI to Alzheimer dementia; BrainSee FDA De Novo approved January 2024.
Workflow: what inputs become what output?
Combines patient brain MRI with cognitive test scores to give a 0-100 progression likelihood score.
Distribution: how it reaches customers
UnverifiedContact-led; no pricing or self-serve shown.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2017 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.